Data from Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Abstract

<div>AbstractPurpose:<p>To conduct an updated exploratory analysis of overall survival (OS) with a longer median follow-up of 73.3 months and evaluate the prognostic value of molecular analysis by circulating tumor DNA (ctDNA).</p>Patients and Methods:<p>Patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR<sup>+</sup>/HER2<sup>−</sup>) advanced breast cancer (ABC) were randomized 2:1 to receive palbociclib (125 mg orally/day; 3/1 week schedule) and fulvestrant (500 mg intramuscularly) or placebo and fulvestrant. This OS analysis was performed when 75% of enrolled patients died (393 events in 521 randomized patients). ctDNA analysis was performed among patients who provided consent.</p>Results:<p>At the data cutoff (August 17, 2020), 258 and 135 deaths occurred in the palbociclib and placebo groups, respectively. The median OS [95% confidence interval (CI)] was 34.8 months (28.8–39.9) in the palbociclib group and 28.0 months (23.5–33.8) in the placebo group (stratified hazard ratio, 0.81; 95% CI, 0.65–0.99). The 6-year OS rate (95% CI) was 19.1% (14.9–23.7) and 12.9% (8.0–19.1) in the palbociclib and placebo groups, respectively. Favorable OS with palbociclib plus fulvestrant compared with placebo plus fulvestrant was observed in most subgroups, particularly in patients with endocrine-sensitive disease, no prior chemotherapy for ABC and low circulating tumor fraction and regardless of <i>ESR1, PIK3CA</i>, or <i>TP53</i> mutation status. No new safety signals were identified.</p>Conclusions:<p>The clinically meaningful improvement in OS associated with palbociclib plus fulvestrant was maintained with >6 years of follow-up in patients with HR<sup>+</sup>/HER2<sup>−</sup> ABC, supporting palbociclib plus fulvestrant as a standard of care in these patients.</p></div>